Loading...
Indian Pharmaceutical Exporter · #5 for Kit · $5.3M export value · DGFT Verified
Cipla Limited is the #5 Indian exporter of Kit with $5.3M in export value and 107 verified shipments. Cipla Limited holds a 1.2% market share in Kit exports across 11 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| 16 |
| 12.6% |
| ZAMBIA | $250.0K | 5 | 7.5% |
| NEW ZEALAND | $102.8K | 7 | 3.1% |
| MADAGASCAR | $12.8K | 2 | 0.4% |
| AUSTRALIA | $2.6K | 2 | 0.1% |
| BELGIUM | $847 | 1 | 0.0% |
Cipla Limited exports Kit to 11 countries. The largest destination is UGANDA accounting for 23.1% of Cipla Limited's Kit shipments, followed by SOUTH AFRICA (20.9%) and KENYA (19.0%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ABACUS PHARMA LTD | UGANDA | $384.3K | 13 |
| CIPLA BRASIL IMPORTADORA E | BRAZIL | $309.7K | 8 |
| CIPLA KENYA LTD C/O IMPERIAL | KENYA | $275.4K | 10 |
| ROZ LOGISTICS | TURKEY | $254.7K | 10 |
| PRIME PHARMACEUTICALS LIMITED | ZAMBIA | $250.0K | 5 |
| MEDPRO PHARMACEUTICA PTY LTD | SOUTH AFRICA | $250.0K | 5 |
| CIPLA QUALITY CHEMICAL INDUSTRIES | UGANDA | $218.1K | 7 |
| CIPLA KENYA LTD | KENYA | $208.7K | 6 |
| MEDPRO PHARMACEUTICA (PTY) LTD.. | SOUTH AFRICA | $179.2K | 4 |
| MEDPRO PHARMACEUTICA (PTY) LTD. | SOUTH AFRICA | $179.0K | 4 |
Cipla Limited supplies Kit to 26 buyers globally. The largest buyer is ABACUS PHARMA LTD (UGANDA), followed by CIPLA BRASIL IMPORTADORA E (BRAZIL) and CIPLA KENYA LTD C/O IMPERIAL (KENYA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $57.8M worth of Kit through 15,000 shipments from 1048 suppliers to 191 countries, serving 3,293 buyers globally. Cipla Limited contributes $5.3M to this total, accounting for 1.2% of India's Kit exports. Cipla Limited ships Kit to 11 countries through 26 buyers.
Cipla Limited's average Kit shipment value is $50.0K per consignment, based on 107 shipments totaling $5.3M. The largest destination is UGANDA (23.1% of Cipla Limited's Kit exports).
Cipla Limited ranks #5 among 1048 Indian Kit exporters with a 1.2% market share. The top 3 exporters are SANDOZ PRIVATE LIMITED ($7.8M), MERIL DIAGNOSTICS PRIVATE LIMITED ($5.6M), MICRO LABS LIMITED ($5.5M). Cipla Limited processed 107 shipments to 11 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PYLOKIT (LANSOPRAZOLE CAPS 30MG+TINIDAZO | $338.0K | 9 |
| ESCLAM KIT (AMOXYCILLIN TRIHYDRATE 1GM+C | $208.7K | 6 |
| PYLOKIT LANSOPRAZOLE CAPS 30MG+TINIDAZO | $150.4K | 6 |
| PYLOKIT (LANSOPRAZOLE CAPS 30MG+TINIDAZOLE TABLETS 500MG+CLARITHROMYCIN TABLETS 250MG KIT) | $150.0K | 3 |
| TYKITICIP 250 MG TABLETS COMMERCIAL GEFITINIB 250 MG 442 PACKS X 3X10'S=13260 NOS | $138.5K | 3 |
| PYLOKIT(LANSOPRAZOLE CAPS 30MG+TINIDAZOL | $100.0K | 2 |
| ESCLAM KIT(AMOXICILLIN 1000MG TABLETS,CLARITHROMYCIN 500MG & ESOMEPRAZOLE 20MG DR TABLETS)[PS:7X1X6X10100PAC=424200 NOS] | $100.0K | 2 |
| ESCLAM KIT (AMOXICILLIN 1000MG TABLETS,CLARITHROMYCIN 500MG AND ESOMEPRAZOLE 20MG DR TABLETS) [19840(PACKS)X7X1X6'S]NOS | $72.0K | 3 |
| ESCLAM KIT (AMOXICILLIN 1000MG TABLETS,CLARITHROMYCIN 500MG AND ESOMEPRAZOLE 20MG DR TABLETS) [17280(PACKS)X7X1X6'S]NOS | $63.7K | 3 |
| PYLOKIT (LANSOPRAZOLE CAPS 30MG+TINIDAZOLE TABLETS 500MG+CLARITHROMYCIN TABLETS250MG KIT) (7 X 1 X 6S(2+2+2) (11970 PANOS | $58.7K | 3 |
Cipla Limited exports 71 distinct Kit formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PYLOKIT (LANSOPRAZOLE CAPS 30MG+TINIDAZO with 9 shipments worth $338.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
What Cipla Limited must comply with to export Kit to its top destination countries
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | LUPIN LIMITED | $5.4M | 108 | 11 | $50.0K |
| 10 | AJANTA PHARMA LIMITED | $5.4M | 339 | 17 | $15.8K |
| 5 | CIPLA LIMITED ★ | $5.3M | 107 | 11 | $50.0K |
| 7 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $3.6M | 73 | 16 | $50.0K |
| 13 | ARKRAY HEALTHCARE PRIVATE LIMITED | $3.1M | 655 | 55 | $4.8K |
Cipla Limited ranks #5 among 1048 Indian Kit exporters. Average shipment value of $50.0K compared to the market average of $55.1K. The closest competitors by value are LUPIN LIMITED and AJANTA PHARMA LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 2,763 | 18.4% |
| SAHAR AIR | 2,534 | 16.9% |
| DELHI AIR CARGO ACC (INDEL4) | 1,051 | 7.0% |
| DELHI AIR | 983 | 6.6% |
| NHAVA SHEVA SEA (INNSA1) | 901 | 6.0% |
| Bombay Air | 541 | 3.6% |
| JNPT/ NHAVA SHEVA SEA | 433 | 2.9% |
| CHENNAI AIR CARGO ACC (INMAA4) | 405 | 2.7% |
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Kit, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Kit — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 191+ countries, 3,293+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Kit exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Kit. For current shipment-level data, contact TransData Nexus.